Shares of Niagen Bioscience (NAGE) are soaring 5.03% in pre-market trading on Monday, following a positive analyst update from H.C. Wainwright. The biotechnology company's stock price surge comes as investors react to the increased confidence in the company's potential.

H.C. Wainwright, a well-respected investment bank and research firm, has raised its price target on Niagen Bioscience to $12 from the previous $11, while maintaining a Buy rating on the shares. This upward revision in the price target suggests that the analyst firm sees additional upside potential in NAGE stock.

While specific details about the rationale behind the price target increase were not provided, it's worth noting that the adjustment follows Niagen Bioscience's recent second-quarter results. The positive analyst sentiment could indicate that the company's financial performance or business outlook has improved, potentially driven by advancements in its research and development pipeline or market positioning in the biotechnology sector.